← Back to Search

Ultrasound Imaging for Pancreatic Cancer

N/A

Recruiting

Led By Kinh Gian Do, MD, PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing whether ultrasounds are as good as CT scans for measuring the size of pancreatic cancer in the liver.

Who is the study for?

This trial is for adults over 18 with pancreatic ductal adenocarcinoma (PDAC) or gastrointestinal (GI) adenocarcinoma that has spread to the liver. They must be scheduled for a routine CT scan. People can't join if they can't handle IV contrast, have very small liver metastases, or if their liver is more than half taken up by tumors.Check my eligibility

What is being tested?

The study tests whether a special computer program analyzing ultrasound images can measure PDAC tumors in the liver as accurately as regular contrast-enhanced CT scans.See study design

What are the potential side effects?

Since this trial involves standard ultrasound imaging and routine CT scans, side effects are minimal but may include discomfort from lying still during procedures and potential reactions to IV contrast used in CT.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer started in the pancreas or GI tract and has spread to my liver.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

measurement differences between ultrasound tumor volumes

Trial Design

1Treatment groups

Experimental Treatment

Group I: research ultrasound (rUS1)Experimental Treatment1 Intervention

Participants will undergo research ultrasound (rUS1) within three days of their routine contrast enhanced CT scan (CECT). A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ultrasound

2003

Completed Phase 3

~49260

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,935 Previous Clinical Trials

588,835 Total Patients Enrolled

Kinh Gian Do, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Richard K.G. Do, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

ultrasound Clinical Trial Eligibility Overview. Trial Name: NCT04837833 — N/A

Gastrointestinal Cancer Research Study Groups: research ultrasound (rUS1)

Gastrointestinal Cancer Clinical Trial 2023: ultrasound Highlights & Side Effects. Trial Name: NCT04837833 — N/A

ultrasound 2023 Treatment Timeline for Medical Study. Trial Name: NCT04837833 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings in this experiment that participants could join?

"According to the clinicaltrials.gov platform, this study is available for patient engagement and has been since April 6th 2021 when it was initially posted. The trial's latest update occurred on May 12th 2022."

Answered by AI

To what magnitude is the current trial involving participants?

"Affirmative. According to the information accessible on clinicaltrials.gov, this trial is currently recruiting study participants. It was initially posted on April 6th 2021 and has since been updated as recently as May 12th 2022. The experiment seeks 20 patients from a single medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

2021. "An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04837833.